Form 8-K - Current report:
SEC Accession No. 0001213900-21-000427
Filing Date
2021-01-05
Accepted
2021-01-05 16:01:18
Documents
8
Period of Report
2020-12-30
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea132523-8k_wizepharma.htm 8-K 72446
2 BID IMPLEMENTATION AGREEMENT ea132523ex2-1_wizepharma.htm EX-2.1 873949
3 FORM OF WARRANT AGENCY AGREEMENT ea132523ex10-1_wizepharma.htm EX-10.1 108883
4 FORM OF CONTINGENT VALUE RIGHTS AGREEMENT ea132523ex10-2_wizepharma.htm EX-10.2 196583
5 SECURITIES PURCHASE AGREEMENT, BETWEEN WIZE PHARMA, INC. AND VARIOUS PURCHASERS, ea132523ex10-3_wizepharma.htm EX-10.3 84413
6 SECURITIES PURCHASE AGREEMENT, BETWEEN WIZE PHARMA, INC. AND NOAM DANENBERG, DAT ea132523ex10-4_wizepharma.htm EX-10.4 86900
7 PRESS RELEASE, DATED JANUARY 4, 2021: WIZE PHARMA RECEIVES BONUS BIOGROUP SHARES ea132523ex99-1_wizepharma.htm EX-99.1 12887
8 GRAPHIC ex99-1_001.jpg GRAPHIC 28024
  Complete submission text file 0001213900-21-000427.txt   1476177
Mailing Address 24 HANAGAR ST HOD HASHARON L3 4527713
Business Address 24 HANAGAR ST HOD HASHARON L3 4527713 972 472 260 0536
Wize Pharma, Inc. (Filer) CIK: 0001218683 (see all company filings)

EIN.: 880445167 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-52545 | Film No.: 21505347
SIC: 2834 Pharmaceutical Preparations